IP Library Granted Patent US 10,676,772
Granted Patent B2
US 10,676,772 · App. 15/953,746 · Granted Jun 9, 2020

Control of protein glycosylation by culture medium supplementation and cell culture process parameters

Inventors: William C. Yang (Cary, NC); Yao-Ming Huang (Cary, NC); Kyle McElearney (Medford, MA); Lia Tescione (Cambridge, MA); James Lambropoulos (Cambridge, MA); An Zhang (Cary, NC); Valerie Liu Tsang (Cary, NC); Thomas Ryll (Lexington, MA); Sangil Lee (Incheon, KR); Dae Sung Lee (Incheon, KR)
Assignees: Biogen MA Inc.; Samsung Bioepis
C12P21/005C12N5/0018C12N2500/20C12N2500/30C12N2500/34C12N2500/40C12N2500/90C12N2501/04C12N2511/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,772
App. No.
15/953,746
Granted
Jun 9, 2020
Kind
B2
Abstract

The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

Claims (37)

1. A method of altering the glycosylation pattern of a recombinant glycoprotein produced in cell culture comprising:

culturing eukaryotic cells engineered to express a recombinant glycoprotein of interest in a cell culture medium, wherein the cell culture medium is supplemented with an additive comprising mycophenolic acid;

wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered relative to the same recombinant glycoprotein produced by the same cells in the same cell culture medium without the additive;

wherein the recombinant glycoprotein of interest comprises at least a portion of: an antibody, an immunoadhesin, a Transforming Growth Factor (TGF) beta superfamily signaling molecule, a blood clotting factor, antibody against TNFR, antibody against growth factor receptors (HER2), TNFR:Fc, combinations thereof, or fragments thereof.

2. The method of claim 1 wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered to better resemble the glycosylation pattern of a reference sample of the glycoprotein.

3. The method of claim 1 , further comprising recovering the recombinant glycoprotein of interest from the cell culture.

4. The method of claim 1 , wherein the alteration of the glycosylation pattern of the recombinant glycoprotein of interest comprises an increased level of afucosylation.

5. The method of claim 1 , wherein the alteration of the glycosylation pattern is achieved without increasing the level of α-gal.

6. The method of claim 1 , wherein the alteration of the glycosylation pattern is achieved without reducing sialic acid levels.

7. The method of claim 1 , wherein the cell culture comprises a growth phase and a protein production phase, and wherein the additive is introduced into the culture medium before or at the same time as the initiation of the protein production phase.

8. The method of claim 1 , wherein the cell culture is conducted in a shake flask.

9. The method of claim 1 , wherein the cell culture is conducted in a stirred-tank bioreactor.

10. The method of claim 9 , wherein the bioreactor has a volume of between about 500 liters and about 30,000 liters.

11. The method of claim 1 , wherein the eukaryotic cells engineered to express the recombinant glycoprotein of interest are selected from the group consisting of CHO cells, HEK cells, NSO cells, PER.C6 cells, 293 cells, HeLa cells, and MDCK cells.

12. The method of claim 1 , wherein the eukaryotic cells engineered to express the recombinant glycoprotein of interest are hybridoma cells.

13. The method of claim 1 , wherein the eukaryotic cells engineered to express the recombinant glycoprotein of interest have been adapted to grow in serum free medium, animal protein free medium or chemically defined medium.

14. The method of claim 1 , wherein the antibody comprises an antibody Fc region, an antigen-binding domain of an antibody, a full antibody, a chimeric antibody, a humanized antibody or human antibody, or a human IgG1 antibody.

15. The method of claim 1 , wherein the immunoadhesin comprises a tumor necrosis factor receptor.

16. The method of claim 1 , wherein the total amount of recombinant glycoprotein produced in the additive-supplemented cell culture medium is equal to the total amount of recombinant glycoprotein produced by the corresponding unsupplemented cell culture medium.

17. The method of claim 1 , wherein the total amount of recombinant glycoprotein produced in the additive-supplemented cell culture medium is decreased by less than 20% of the total amount of recombinant glycoprotein produced by the corresponding unsupplemented cell culture medium.

18. The method of claim 1 , wherein the specific productivity of the engineered eukaryotic cells maintained in the additive-supplemented cell culture medium is equal to the specific productivity of the same cells maintained in the corresponding unsupplemented cell culture medium.

19. The method of claim 1 , wherein the cell culture is a perfusion culture.

20. The method of claim 1 , wherein the supplemented cell culture medium comprises between 1 μM and 50 μM mycophenolic acid.

21. The method of claim 20 , wherein the mycophenolic acid is introduced into the cell culture medium as part of a feed medium, or as one or more boli from a distinct stock solution.

22. The method of claim 1 , wherein the method further comprises controlling or modulating cell culture temperature.

23. The method of claim 22 , wherein the cell culture temperature is about 25 to about 42° C.

24. The method of claim 22 , wherein the mycophenolic acid is introduced at the same time as the cell culture temperature is controlled or modulated.

25. The method of claim 22 , wherein the mycophenolic acid is introduced at a different time than the time when the cell culture temperature is controlled or modulated.

26. The method of claim 1 , wherein the method further comprises controlling or modulating cell culture seed density.

27. A method of altering the glycosylation pattern of a recombinant glycoprotein produced in cell culture comprising:

culturing eukaryotic cells engineered to express a recombinant glycoprotein of interest in a cell culture medium, wherein the cell culture medium is supplemented with an additive comprising mycophenolic acid;

wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered relative to the same recombinant glycoprotein produced by the same cells in the same cell culture medium without the additive;

wherein the eukaryotic cells engineered to express the recombinant glycoprotein of interest are hybridoma cells.

28. A method of altering the glycosylation pattern of a recombinant glycoprotein produced in cell culture comprising:

culturing eukaryotic cells engineered to express a recombinant glycoprotein of interest in a cell culture medium, wherein the cell culture medium is supplemented with an additive comprising mycophenolic acid;

wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered relative to the same recombinant glycoprotein produced by the same cells in the same cell culture medium without the additive;

wherein the cell culture is a perfusion culture.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2018
From: YANG, WILLIAM; HUANG, YAO MING; MCELEARNEY, KYLE; TESCIONE, LIA; LAMBROPOULOS, JAMES; ZHANG, AN; TSANG, VALERIE; RYLL, THOMAS
To: BIOGEN MA INC.
Reel/Frame 045963/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2018
From: LEE, SANGIL; LEE, DAE SUNG
To: SAMSUNG BIOEPIS
Reel/Frame 045963/0117 →
Continuity (5)
Continuation 15000522 · Jan 19, 2016
Continuation 14625559 · Feb 18, 2015
Continuation In Part PCTUS2014051727 · Aug 19, 2014
Provisional Application 61867592 · Aug 19, 2013
Related Publication 20190085369A1 · Mar 21, 2019